These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 26348403)
1. Conformationally selective biophysical assay for influenza vaccine potency determination. Wen Y; Han L; Palladino G; Ferrari A; Xie Y; Carfi A; Dormitzer PR; Settembre EC Vaccine; 2015 Oct; 33(41):5342-5349. PubMed ID: 26348403 [TBL] [Abstract][Full Text] [Related]
2. Trypsin pre-treatment corrects SRID over-estimation of immunologically active, pre-fusion HA caused by mixed immunoprecipitin rings. Wen Y; Palladino G; Xie Y; Ferrari A; Ma X; Han L; Dormitzer PR; Settembre EC Vaccine; 2016 Jun; 34(29):3388-95. PubMed ID: 27154389 [TBL] [Abstract][Full Text] [Related]
3. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity. Wen Y; Palladino G; Xie Y; Ferrari A; Settembre EC Vaccine; 2018 May; 36(21):3010-3017. PubMed ID: 29680201 [TBL] [Abstract][Full Text] [Related]
4. Selective Capture and Determination of Receptor-Binding Hemagglutinin in Influenza Vaccine Preparations Using a Coupled Receptor-Binding/RP-HPLC Assay. Lorbetskie B; Cunningham AM; Lemieux M; Durno L; Farnsworth A; Wang J; Li C; Li X; Gilbert M; Sauvé S; Girard M Anal Chem; 2019 Jul; 91(14):8908-8917. PubMed ID: 31251585 [TBL] [Abstract][Full Text] [Related]
5. Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Lorbetskie B; Wang J; Gravel C; Allen C; Walsh M; Rinfret A; Li X; Girard M Vaccine; 2011 Apr; 29(18):3377-89. PubMed ID: 21397719 [TBL] [Abstract][Full Text] [Related]
6. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines. Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263 [TBL] [Abstract][Full Text] [Related]
7. Reference antigen-free and antibody-free LTD-IDMS assay for influenza H7N9 vaccine in vitro potency determination. Morgenstern K; Xie Y; Palladino G; Barr JR; Settembre EC; Williams TL; Wen Y Vaccine; 2018 Oct; 36(41):6144-6151. PubMed ID: 30194004 [TBL] [Abstract][Full Text] [Related]
8. Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine. Li C; Xu K; Hashem A; Shao M; Liu S; Zou Y; Gao Q; Zhang Y; Yuan L; Xu M; Li X; Wang J Hum Vaccin Immunother; 2015; 11(6):1351-6. PubMed ID: 25970793 [TBL] [Abstract][Full Text] [Related]
9. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687 [TBL] [Abstract][Full Text] [Related]
10. A hemagglutinin quantification method for development of an influenza pandemic vaccine using size exclusion high performance liquid chromatography. Roh HS; Song HM; Yun BR; Kang HK; Choi KS; Park YJ; Kim DS; Kim SH; Mo IP; An BS; Ahn CY Mol Med Rep; 2015 Apr; 11(4):2819-24. PubMed ID: 25482872 [TBL] [Abstract][Full Text] [Related]
11. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Kapteyn JC; Porre AM; de Rond EJ; Hessels WB; Tijms MA; Kessen H; Slotboom AM; Oerlemans MA; Smit D; van der Linden J; Schoen P; Thus JL Vaccine; 2009 Feb; 27(9):1468-77. PubMed ID: 19110022 [TBL] [Abstract][Full Text] [Related]
12. An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines. Bodle J; Vandenberg K; Laurie K; Barr IG; Zhang Y; Rockman S Front Immunol; 2023; 14():1147028. PubMed ID: 37033922 [TBL] [Abstract][Full Text] [Related]
17. Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in egg-derived influenza vaccines. Legastelois I; Chevalier M; Bernard MC; de Montfort A; Fouque M; Pilloud A; Serraille C; Devard N; Engel O; Sodoyer R; Moste C J Virol Methods; 2011 Dec; 178(1-2):129-36. PubMed ID: 21907241 [TBL] [Abstract][Full Text] [Related]
18. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies. Verma S; Soto J; Vasudevan A; Schmeisser F; Alvarado-Facundo E; Wang W; Weiss CD; Weir JP PLoS One; 2017; 12(4):e0175733. PubMed ID: 28423025 [TBL] [Abstract][Full Text] [Related]
19. Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza. Vodeiko GM; Weir JP Influenza Other Respir Viruses; 2012 May; 6(3):176-87. PubMed ID: 21902817 [TBL] [Abstract][Full Text] [Related]
20. Hemagglutinin Quantitative ELISA-based Potency Assay for Trivalent Seasonal Influenza Vaccine Using Group-Specific Universal Monoclonal Antibodies. Chae W; Kim P; Kim H; Cheong YC; Kim YS; Kang SM; Seong BL Sci Rep; 2019 Dec; 9(1):19675. PubMed ID: 31873147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]